Phillip Thomas Hawkins

Phillip Thomas Hawkins's AcademicInfluence.com Rankings

Chemistry

#1412

World Rank

#2116

Historical Rank

Organic Chemistry

#165

World Rank

#211

Historical Rank

chemistry Degrees

Phillip Thomas Hawkins

Mathematics

#4491

World Rank

#6368

Historical Rank

Algebraic Geometry

#89

World Rank

#95

Historical Rank

Number Theory

#106

World Rank

#143

Historical Rank

Measure Theory

#375

World Rank

#553

Historical Rank

mathematics Degrees

Download Badge

Chemistry
Mathematics

Phillip Thomas Hawkins's Degrees

Masters Mathematics University of Oxford

Why Is Phillip Thomas Hawkins Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Phillip Thomas Hawkins FRS is a molecular biologist, senior group leader at the Babraham Institute. Phill Hawkins has contributed much to the understanding of inositol lipids functions in eukaryotic cells. Together with his long-time collaborator Leonard R Stephens, he established that PtdInsP2 is the main substrate of receptor-controlled Type 1 phosphoinositide 3-kinases , thus identifying PtdInsP3 as the key output signal produced by this enzyme. They identified and isolated the GPCR-activated Type 1B PI3K and, in a sustained body of work, defined its structure, explained its complex pattern of regulation by GβΥ and Ras, and proved its role in inflammatory events in vivo. They - in parallel with Dario Alessi - identified phosphoinositide-dependent kinase-1 as the PtdInsP3-activated link between PI3K-1 activation and protein kinase B activation, a key pathway through which PtdInsP3 formation regulates cell proliferation and survival.

(See a Problem?)

Phillip Thomas Hawkins's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. (2004) (1667)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis (2018) (1423)
Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. (1997) (1251)
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis (2005) (1202)
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis (2016) (1108)
Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. (2000) (1079)
Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. (1998) (1063)
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis (1997) (984)
Natural history and outcome in systemic AA amyloidosis. (2007) (847)
PI3K signalling: the path to discovery and understanding (2012) (815)
Safety and efficacy of RNAi therapy for transthyretin amyloidosis. (2013) (782)
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. (2006) (774)
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. (2012) (693)
Targeting C-reactive protein for the treatment of cardiovascular disease (2006) (651)
Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. (1993) (637)
Use of canakinumab in the cryopyrin-associated periodic syndrome. (2009) (620)
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. (2002) (607)
Signalling through Class I PI3Ks in mammalian cells. (2006) (592)
Cardiovascular Magnetic Resonance in Cardiac Amyloidosis (2005) (573)
PDGF stimulates an increase in GTP–Rac via activation of phosphoinositide 3-kinase (1995) (553)
Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. (2004) (544)
A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein βγ subunits (1994) (544)
Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. (2013) (536)
The Gβγ Sensitivity of a PI3K Is Dependent upon a Tightly Associated Adaptor, p101 (1997) (527)
Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein (2001) (523)
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis (2002) (521)
Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ (2000) (506)
Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage (2013) (503)
Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. (1990) (503)
Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. (2003) (482)
Systemic amyloidosis (2016) (458)
Activation of phosphoinositide 3-kinase is required for PDGF-stimulated membrane ruffling (1994) (443)
Activation of the small GTP-binding proteins rho and rac by growth factor receptors. (1995) (440)
Agonist-stimulated synthesis of phosphatidylinositol(3,4,5)-trisphosphate: a new intracellular signalling system? (1993) (437)
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy (2003) (420)
Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis (2015) (416)
PtdIns(3)P regulates the neutrophil oxidase complex by binding to the PX domain of p40phox (2001) (410)
Rapid breakdown of phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate in rat hepatocytes stimulated by vasopressin and other Ca2+-mobilizing hormones. (1983) (406)
Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B (1998) (389)
Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP‐met30) (1991) (389)
PI3K signalling in inflammation. (2015) (361)
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. (2013) (351)
Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. (2002) (351)
Native T1 mapping in transthyretin amyloidosis. (2014) (349)
Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. (2006) (344)
Phosphoinositide 3‐kinase‐dependent activation of Rac (2003) (339)
Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. (2005) (334)
A new staging system for cardiac transthyretin amyloidosis (2018) (333)
EULAR recommendations for the management of familial Mediterranean fever (2016) (327)
T1 mapping and survival in systemic light-chain amyloidosis (2014) (321)
Evaluation and management of the cardiac amyloidosis. (2007) (315)
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits (2010) (311)
Identification of ARAP3, a novel PI3K effector regulating both Arf and Rho GTPases, by selective capture on phosphoinositide affinity matrices. (2002) (306)
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. (2015) (299)
Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease (2012) (297)
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. (2015) (296)
Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. (2000) (295)
Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome (2013) (289)
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. (2010) (279)
The crystal structure of the PX domain from p40(phox) bound to phosphatidylinositol 3-phosphate. (2001) (278)
Roles of PI3Ks in leukocyte chemotaxis and phagocytosis. (2002) (273)
T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. (2013) (270)
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes (2009) (269)
Magnetic Resonance in Transthyretin Cardiac Amyloidosis. (2017) (268)
Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene (1997) (266)
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. (2011) (258)
Cardiovascular Magnetic Resonance and prognosis in cardiac amyloidosis (2008) (256)
Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry (2011) (252)
Quantification of Myocardial Extracellular Volume Fraction in Systemic AL Amyloidosis: An Equilibrium Contrast Cardiovascular Magnetic Resonance Study (2013) (252)
CMR-based differentiation of AL and ATTR cardiac amyloidosis. (2014) (241)
Human plasma fibrinogen is synthesized in the liver. (2007) (240)
P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac. (2002) (240)
Updates in Cardiac Amyloidosis: A Review (2012) (240)
Systemic Amyloidosis in England: an epidemiological study (2013) (233)
The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. (1997) (232)
Systemic immunoglobulin light chain amyloidosis (2018) (231)
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. (2007) (229)
Platelet-derived growth factor stimulates synthesis of Ptdlns(3,4,5)P3 by activating a Ptdlns(4,5)P2 3-OH kinase (1992) (227)
SCFAs Induce Mouse Neutrophil Chemotaxis through the GPR43 Receptor (2011) (226)
Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. (1994) (211)
Inositol 1,3,4,5-tetrakisphosphate and not phosphatidylinositol 3,4-bisphosphate is the probable precursor of inositol 1,3,4-trisphosphate in agonist-stimulated parotid gland. (1986) (208)
A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein beta gamma subunits. (1994) (204)
DIAGNOSTIC RADIONUCLIDE IMAGING OF AMYLOID: BIOLOGICAL TARGETING BY CIRCULATING HUMAN SERUM AMYLOID P COMPONENT (1988) (204)
The genetic basis of autosomal dominant familial Mediterranean fever. (2000) (203)
Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. (2003) (201)
Systemic amyloidosis. (2006) (200)
Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. (2019) (200)
Granulocyte macrophage‐colony stimulating factor stimulates both association and activation of phosphoinositide 3OH‐kinase and src‐related tyrosine kinase(s) in human myeloid derived cells. (1993) (199)
Neutrophils from p40phox−/− mice exhibit severe defects in NADPH oxidase regulation and oxidant-dependent bacterial killing (2006) (196)
The detection, purification, structural characterization, and metabolism of diphosphoinositol pentakisphosphate(s) and bisdiphosphoinositol tetrakisphosphate(s). (1993) (196)
Phosphatidylinositol 3-kinase-γ activates Bruton’s tyrosine kinase in concert with Src family kinases (1997) (194)
Bleeding symptoms and coagulation abnormalities in 337 patients with AL‐amyloidosis (2000) (192)
Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations (2014) (190)
The PX domain: a new phosphoinositide-binding module. (2002) (189)
P-Rex1, a PtdIns(3,4,5)P3- and Gβγ-Regulated Guanine-Nucleotide Exchange Factor for Rac (2002) (187)
Eprodisate for the treatment of renal disease in AA amyloidosis. (2007) (183)
Moving towards a Better Understanding of Chemotaxis (2008) (179)
Cardiac transplantation for amyloid heart disease: the United Kingdom experience. (2004) (178)
Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. (2006) (176)
Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. (2014) (175)
Evolving landscape in the management of transthyretin amyloidosis (2015) (173)
Phosphatidylinositol 3-phosphate is generated in phagosomal membranes (2001) (171)
AMYLOIDOSIS: A REVIEW OF RECENT DIAGNOSTIC AND THERAPEUTIC DEVELOPMENTS (1997) (169)
P-Rex1 Regulates Neutrophil Function (2005) (168)
Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. (2006) (163)
Structure of Lipid Kinase p110β/p85β Elucidates an Unusual SH2-Domain-Mediated Inhibitory Mechanism (2011) (163)
Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. (2012) (162)
Receptor stimulated accumulation of phosphatidylinositol (3,4,5)‐trisphosphate by G‐protein mediated pathways in human myeloid derived cells. (1993) (161)
Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. (2005) (156)
p84, a New Gβγ-Activated Regulatory Subunit of the Type IB Phosphoinositide 3-Kinase p110γ (2005) (155)
Acute phase response and evolution of familial Mediter ranean fever (1999) (154)
PI(3)Kgamma has an important context-dependent role in neutrophil chemokinesis. (2007) (148)
Proinflammatory Effects of Bacterial Recombinant Human C-Reactive Protein Are Caused by Contamination With Bacterial Products, Not by C-Reactive Protein Itself (2005) (148)
Native T1 and Extracellular Volume in Transthyretin Amyloidosis. (2019) (148)
Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. (2015) (147)
PI(3)Kγ has an important context-dependent role in neutrophil chemokinesis (2007) (147)
Rapid formation of inositol 1,3,4,5-tetrakisphosphate and inositol 1,3,4-trisphosphate in rat parotid glands may both result indirectly from receptor-stimulated release of inositol 1,4,5-trisphosphate from phosphatidylinositol 4,5-bisphosphate. (1986) (146)
Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis (2002) (144)
Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. (2012) (141)
PtdIns3P binding to the PX domain of p40phox is a physiological signal in NADPH oxidase activation (2006) (139)
Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. (2009) (139)
PI3Kβ Plays a Critical Role in Neutrophil Activation by Immune Complexes (2011) (138)
Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. (1992) (137)
Inhibition of iron-catalysed hydroxyl radical formation by inositol polyphosphates: a possible physiological function for myo-inositol hexakisphosphate. (1993) (137)
Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis (2017) (136)
Initiation and maintenance of NGF-stimulated neurite outgrowth requires activation of a phosphoinositide 3-kinase. (1996) (133)
A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. (2015) (132)
Myocardial Edema and Prognosis in Amyloidosis. (2018) (132)
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease (2008) (131)
Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion (2014) (130)
Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement. (2016) (129)
Amyloidosis and the respiratory tract (1999) (129)
Acute phase response and evolution of familial Mediterranean fever. (1999) (128)
ARAP3 Is a PI3K- and Rap-Regulated GAP for RhoA (2004) (127)
Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. (2002) (127)
PTEN Regulates PI(3,4)P2 Signaling Downstream of Class I PI3K (2017) (126)
Guidelines on the diagnosis and management of AL amyloidosis (2004) (125)
Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis (2010) (125)
Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis (2020) (123)
Outcome in renal Al amyloidosis after chemotherapy. (2011) (123)
The cytotoxic T cell proteome and its shaping by mammalian Target of Rapamycin (2015) (122)
Cardiac transthyretin amyloidosis (2012) (122)
Characterization of a phosphatidylinositol-specific phosphoinositide 3-kinase from mammalian cells (1994) (121)
Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. (2006) (118)
Guidelines on the diagnosis and investigation of AL amyloidosis (2015) (118)
Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study (2011) (117)
Automated Pixel-Wise Quantitative Myocardial Perfusion Mapping by CMR to Detect Obstructive Coronary Artery Disease and Coronary Microvascular Dysfunction: Validation Against Invasive Coronary Physiology. (2019) (117)
Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. (2011) (116)
Phosphoinositide 3-kinases as drug targets in cancer. (2005) (116)
Cardiovascular magnetic resonance for amyloidosis (2015) (115)
Liver transplantation in transthyretin-related familial amyloid polyneuropathy (2004) (114)
Solid Organ Transplantation in AL Amyloidosis (2010) (114)
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III) (2014) (113)
FENS-1 and DFCP1 are FYVE domain-containing proteins with distinct functions in the endosomal and Golgi compartments. (2001) (110)
Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kγ (2000) (109)
Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid (2017) (109)
Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy (2020) (109)
Activation of Phosphoinositide 3-Kinase γ by Ras (2002) (108)
A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. (2019) (106)
Guidelines on the management of AL amyloidosis (2015) (106)
Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. (1999) (106)
Receptor specificity of growth factor-stimulated synthesis of 3-phosphorylated inositol lipids in Swiss 3T3 cells. (1992) (105)
Pyrin/marenostrin mutations in familial Mediterranean fever. (1998) (104)
P‐Rex2, a new guanine‐nucleotide exchange factor for Rac (2004) (104)
Gbetagammas and the Ras binding domain of p110gamma are both important regulators of PI(3)Kgamma signalling in neutrophils. (2006) (103)
Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. (1990) (102)
A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis (2015) (102)
SAA1 alleles as risk factors in reactive systemic AA amyloidosis. (1998) (101)
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. (2019) (101)
Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis. (2020) (100)
Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis (2015) (100)
Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. (2015) (98)
Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation (2020) (98)
Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. (1996) (98)
Prevalence and significance of the familial Mediterranean fever gene mutation encoding pyrin Q148. (2001) (98)
PI3K signaling in neutrophils. (2010) (98)
Prevalence of Cardiac Amyloidosis in Patients Referred for Transcatheter Aortic Valve Replacement (2018) (97)
Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles. (2019) (95)
Regulation of P-Rex1 by Phosphatidylinositol (3,4,5)-Trisphosphate and Gβγ Subunits* (2005) (95)
CD18-dependent activation of the neutrophil NADPH oxidase during phagocytosis of Escherichia coli or Staphylococcus aureus is regulated by class III but not class I or II PI3Ks. (2008) (95)
Natural history and outcome of light chain deposition disease. (2015) (94)
Perspectives in treatment of AL amyloidosis (2008) (93)
Gβγs and the Ras binding domain of p110γ are both important regulators of PI3Kγ signalling in neutrophils (2006) (93)
A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue (2015) (93)
Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis (2018) (91)
Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis. (1993) (91)
Protein Kinase B and Rac Are Activated in Parallel within a Phosphatidylinositide 3OH-kinase-controlled Signaling Pathway* (1998) (89)
Emerging evidence of signalling roles for PI(3,4)P2 in Class I and II PI3K-regulated pathways. (2016) (88)
Late-Onset Cryopyrin-Associated Periodic Syndromes Caused by Somatic NLRP3 Mosaicism—UK Single Center Experience (2017) (88)
Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis (2014) (88)
The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. (1994) (87)
AA amyloidosis complicating the hereditary periodic fever syndromes. (2003) (87)
myo-inositol pentakisphosphates. Structure, biological occurrence and phosphorylation to myo-inositol hexakisphosphate. (1991) (86)
Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component (1988) (86)
Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. (2020) (86)
Pathophysiology and treatment of systemic amyloidosis (2013) (85)
Characterizing the Interactions between the Two Subunits of the p101/p110γ Phosphoinositide 3-Kinase and Their Role in the Activation of This Enzyme by Gβγ Subunits* (1999) (85)
Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation (1998) (84)
p84, a new Gbetagamma-activated regulatory subunit of the type IB phosphoinositide 3-kinase p110gamma. (2005) (84)
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis (2014) (83)
Outcome of autologous stem cell transplantation for AL amyloidosis in the UK (2006) (83)
Two distinct functions for PI3-kinases in macropinocytosis (2013) (81)
Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo. (1994) (81)
Hereditary auto-inflammatory disorders and biologics (2006) (81)
Pathogenetic mechanisms of amyloid A amyloidosis (2013) (81)
Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. (2008) (80)
The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: A double-blind, placebo-controlled trial. (2004) (80)
CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy. (2018) (79)
PI3Kγ Is a Key Regulator of Inflammatory Responses and Cardiovascular Homeostasis (2007) (79)
International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors (2017) (78)
Structure, Folding Dynamics, and Amyloidogenesis of D76N β2-Microglobulin (2013) (77)
The emerging role of interleukin-1β in autoinflammatory diseases. (2011) (77)
Treatment of amyloidosis. (1995) (76)
Systemic amyloidosis and the gastrointestinal tract (2009) (74)
Hereditary renal amyloidosis associated with variant lysozyme in a large English family. (1999) (73)
Metabolic and structural evidence for the existence of a third species of polyphosphoinositide in cells: D-phosphatidyl-myo-inositol 3-phosphate. (1989) (72)
Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy. (2018) (72)
Amyloidosis and the lung (2006) (72)
Synthesis of phosphatidylinositol 3,4,5-trisphosphate in permeabilized neutrophils regulated by receptors and G-proteins. (1993) (71)
Phosphoinositide hydrolysis by guanosine 5'-[gamma-thio]triphosphate-activated phospholipase C of turkey erythrocyte membranes. (1988) (71)
Cardiac amyloidosis (2018) (71)
Activation of phosphoinositide 3-kinase gamma by Ras. (2002) (71)
A new approach to measuring phosphoinositides in cells by mass spectrometry. (2014) (70)
Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component (1991) (70)
'Fragile' liver and massive hepatic haemorrhage due to hereditary amyloidosis. (1996) (70)
Rapid automated enzyme immunoassay of serum amyloid A. (1994) (70)
Organ Transplantation in Hereditary Apolipoprotein AI Amyloidosis (2006) (70)
Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome. (2018) (70)
AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. (2008) (69)
Imaging amyloidosis with radiolabelled SAP (1995) (69)
Infusion of Pharmaceutical-Grade Natural Human C-Reactive Protein Is Not Proinflammatory in Healthy Adult Human Volunteers (2014) (68)
Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic StenosisCLINICAL PERSPECTIVE (2016) (68)
Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component (2009) (68)
Reduction in CMR Derived Extracellular Volume with Patisiran Indicates Cardiac Amyloid Regression. (2020) (68)
Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome (2012) (68)
The Molecular Basis of the Differential Subcellular Localization of FYVE Domains* (2004) (67)
Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. (1998) (67)
Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. (1996) (67)
Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis (2002) (66)
Synthesis of myo-inositol 1,3,4,5,6-pentakisphosphate from inositol phosphates generated by receptor activation. (1988) (66)
PtdIns3P and Rac direct the assembly of the NADPH oxidase on a novel, pre-phagosomal compartment during FcR-mediated phagocytosis in primary mouse neutrophils. (2010) (65)
Lysophosphatidylinositol-Acyltransferase-1 (LPIAT1) Is Required to Maintain Physiological Levels of PtdIns and PtdInsP2 in the Mouse (2013) (65)
Inactivation of the Class II PI3K-C2β Potentiates Insulin Signaling and Sensitivity (2015) (64)
Analysis of inositol metabolites produced by Saccharomyces cerevisiae in response to glucose stimulation. (1993) (63)
Clinical impact of a targeted next-generation sequencing gene panel for autoinflammation and vasculitis (2017) (63)
Class IA Phosphoinositide 3-Kinase β and δ Regulate Neutrophil Oxidase Activation in Response to Aspergillus fumigatus Hyphae (2011) (63)
Long-term survival in systemic amyloid A amyloidosis complicating Crohn's disease. (1997) (62)
C-reactive protein and bacterial infection in preterm infants (1990) (61)
Use of Anakinra (Kineret) in the Treatment of Familial Cold Autoinflammatory Syndrome with a 16-Month Follow-Up (2008) (61)
Multiple metabolic pools of phosphoinositides and phosphatidate in human erythrocytes incubated in a medium that permits rapid transmembrane exchange of phosphate. (1987) (61)
L-myo-inositol 1,4,5,6-tetrakisphosphate is present in both mammalian and avian cells. (1988) (61)
Diagnostic imaging of cardiac amyloidosis (2020) (60)
Cardiac amyloidosis: where are we today? (2015) (60)
Primary localised amyloidosis of the orbit. (1996) (58)
Turkey erythrocyte membranes as a model for regulation of phospholipase C by guanine nucleotides. (1987) (57)
A novel variant of transthyretin, 59Thr-->Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family. (1995) (56)
Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease. (2004) (56)
Characterization of metal ion-induced [3H]inositol hexakisphosphate binding to rat cerebellar membranes. (1993) (56)
Clinical characteristics in subjects with NLRP3 V198M diagnosed at a single UK center and a review of the literature (2013) (55)
Phosphoproteomic Analyses of Interleukin 2 Signaling Reveal Integrated JAK Kinase-Dependent and -Independent Networks in CD8+ T Cells (2016) (55)
ARAP3 is essential for formation of lamellipodia after growth factor stimulation (2006) (54)
AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome: a report of two cases. (2006) (54)
Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac Amyloidosis. (2016) (54)
Allogeneic bone marrow transplantation for systemic AL amyloidosis (1998) (54)
Measurement of Tissue interstitial volume in healthy patients and those with amyloidosis with equilibrium contrast-enhanced MR imaging. (2013) (54)
The labelling of polyphosphoinositides with [32P]Pi and the accumulation of inositol phosphates in vasopressin-stimulated hepatocytes. (1986) (54)
A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK (2015) (54)
The role of phosphoinositides and phosphorylation in regulation of NADPH oxidase. (2004) (53)
Regulation of PTEN inhibition by the pleckstrin homology domain of P-REX2 during insulin signaling and glucose homeostasis (2013) (53)
Plasminogen activation triggers transthyretin amyloidogenesis in vitro (2018) (52)
The GTPase-activating protein ARAP3 regulates chemotaxis and adhesion-dependent processes in neutrophils. (2011) (52)
European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis. (2016) (52)
P-Rex1 directly activates RhoG to regulate GPCR-driven Rac signalling and actin polarity in neutrophils (2014) (52)
Activation of phosphatidylinositol 4,5-bisphosphate supply by agonists and non-hydrolysable GTP analogues. (1993) (51)
Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. (2015) (51)
Priming of human neutrophil superoxide generation by tumour necrosis factor‐α is signalled by enhanced phosphatidylinositol 3,4,5‐trisphosphate but not inositol 1,4,5‐trisphosphate accumulation (1998) (51)
Phosphatidylinositol 3-kinase-gamma activates Bruton's tyrosine kinase in concert with Src family kinases. (1997) (50)
Coincident signals from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3Kβ in myeloid cells (2016) (50)
High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis. (2019) (50)
Regulation of P-Rex1 by phosphatidylinositol (3,4,5)-trisphosphate and Gbetagamma subunits. (2005) (50)
Amyloidosis: new strategies for treatment. (2003) (50)
Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease. (1994) (48)
Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre (2017) (48)
Phosphorylation of threonine 154 in p40phox is an important physiological signal for activation of the neutrophil NADPH oxidase. (2010) (48)
PI3K Class IB Pathway (2007) (48)
Heart Transplantation for Homozygous Familial Transthyretin (TTR) V122I Cardiac Amyloidosis (2008) (48)
PI3K Class IB Pathway in Neutrophils (2007) (47)
Brief Report: Association of Tumor Necrosis Factor Receptor–Associated Periodic Syndrome With Gonosomal Mosaicism of a Novel 24‐Nucleotide TNFRSF1A Deletion (2016) (47)
DAPP1 undergoes a PI 3-kinase-dependent cycle of plasma-membrane recruitment and endocytosis upon cell stimulation (2000) (47)
Phosphatidylinositol 4,5-bisphosphate hydrolysis in turkey erythrocytes is regulated by P2y purinoceptors. (1989) (47)
The role of PI3Ks in the regulation of the neutrophil NADPH oxidase. (2007) (46)
Functional Redundancy of Class I Phosphoinositide 3-Kinase (PI3K) Isoforms in Signaling Growth Factor-Mediated Human Neutrophil Survival (2012) (46)
Synthesis and biological evaluation of phosphatidylinositol phosphate affinity probes. (2010) (45)
Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study (2017) (45)
The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis (2019) (45)
GPCR activation of Ras and PI3Kγ in neutrophils depends on PLCβ2/β3 and the RasGEF RasGRP4 (2012) (45)
Dictyostelium uses ether‐linked inositol phospholipids for intracellular signalling (2014) (45)
cAMP Signaling of Adenylate Cyclase Toxin Blocks the Oxidative Burst of Neutrophils through Epac-Mediated Inhibition of Phospholipase C Activity (2017) (45)
L-myo-inositol 1,4,5,6-tetrakisphosphate (3-hydroxy)kinase. (1988) (44)
Autosomal dominant familial Mediterranean fever in Northern European Caucasians associated with deletion of p.M694 residue—a case series and genetic exploration (2017) (44)
Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR) (2020) (44)
The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. (2012) (43)
Developments in the scientific and clinical understanding of autoinflammatory disorders (2009) (43)
D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile (2016) (43)
Whole-Exome Sequencing Revealing Somatic NLRP3 Mosaicism in a Patient With Chronic Infantile Neurologic, Cutaneous, Articular Syndrome (2013) (43)
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens (2014) (43)
Brief Report: Severe Inflammation Following Vaccination Against Streptococcus pneumoniae in Patients With Cryopyrin‐Associated Periodic Syndromes (2016) (42)
Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis (2020) (41)
Identifying Cardiac Amyloid in Aortic Stenosis (2020) (40)
Outcomes of Heart Transplantation for Cardiac Amyloidosis: Subanalysis of the Spanish Registry for Heart Transplantation (2009) (40)
The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract. (2002) (40)
Hereditary systemic amyloidosis with renal involvement. (2003) (40)
Grand Rounds - Hammersmith Hospital: Cardiac transplantation for AL amyloidosis (1994) (40)
Amyloid and the gut. (1997) (40)
Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred (2014) (39)
Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner (2020) (39)
Signalling via phosphoinositide 3OH kinases. (1997) (39)
Characterizing the interactions between the two subunits of the p101/p110gamma phosphoinositide 3-kinase and their role in the activation of this enzyme by G beta gamma subunits. (1999) (39)
Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis (2007) (38)
Quantitative measurement of phosphatidylinositol 3,4,5-trisphosphate. (2007) (38)
DPD Quantification in Cardiac Amyloidosis (2020) (38)
Phosphatidylinositol metabolism in cells transformed by polyomavirus middle T antigen (1990) (37)
LL5β Is a Phosphatidylinositol (3,4,5)-Trisphosphate Sensor That Can Bind the Cytoskeletal Adaptor, γ-Filamin* 210 (2003) (37)
Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis (2018) (37)
Validation of the Criteria of Response to Treatment In AL Amyloidosis. (2010) (37)
The regulatory subunits of PI3Kγ control distinct neutrophil responses (2015) (37)
The significance of paired MEFV mutations in individuals without symptoms of familial Mediterranean fever (2002) (37)
General synthesis of 3-phosphorylated myo-inositol phospholipids and derivatives (1999) (36)
Drug Insight: emerging therapies for amyloidosis (2006) (36)
An Israeli Arab patient with a de novo TNFRSF1A mutation causing tumor necrosis factor receptor-associated periodic syndrome. (2002) (36)
Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C‐reactive protein, for clinical use (2012) (35)
Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience. (2014) (35)
How is the acyl chain composition of phosphoinositides created and does it matter? (2019) (32)
RhoG Regulates the Neutrophil NADPH Oxidase1 (2006) (32)
Inositol 1,2-cyclic 4,5-trisphosphate is not a product of muscarinic receptor-stimulated phosphatidylinositol 4,5-bisphosphate hydrolysis in rat parotid glands. (1987) (32)
Analysis of the metabolic turnover of the individual phosphate groups of phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate. Validation of novel analytical techniques by using 32P-labelled lipids from erythrocytes. (1984) (32)
Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis (2011) (32)
Prospective comparison of novel dark blood late gadolinium enhancement with conventional bright blood imaging for the detection of scar (2017) (32)
Diagnosis and monitoring of amyloidosis. (1994) (31)
Use of the GRP1 PH domain as a tool to measure the relative levels of PtdIns(3,4,5)P3 through a protein-lipid overlay approach Published, JLR Papers in Press, November 27, 2006. (2007) (31)
Synergistic activation of JNK/SAPK by interleukin-1 and platelet-derived growth factor is independent of Rac and Cdc42. (1999) (31)
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma (2017) (31)
Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy (2019) (31)
Quantitation of 99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis (2018) (31)
Src Family Kinases Mediate Receptor-stimulated, Phosphoinositide 3-Kinase-dependent, Tyrosine Phosphorylation of Dual Adaptor for Phosphotyrosine and 3-Phosphoinositides-1 in Endothelial and B Cell Lines* (2001) (30)
Hereditary cardiac amyloidosis associated with the transthyretin Ile122 mutation in a white man (1999) (30)
Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel (2017) (30)
Definition of Organ Involvement and Treatment Response in Primary Systemic Amyloidosis (AL): A Consensus Opinion from the 10th International Symposium on Amyloid and Amyloidosis. (2004) (30)
In-depth PtdIns(3,4,5)P3 signalosome analysis identifies DAPP1 as a negative regulator of GPVI-driven platelet function. (2017) (30)
Inflammatory Bowel Disease and Systemic AA Amyloidosis (2013) (30)
Mechanism of the regulation of type IB phosphoinositide 3OH-kinase byG-protein betagamma subunits. (2002) (30)
An analysis of myo-[3H]inositol trisphosphates found in myo-[3H]inositol prelabelled avian erythrocytes. (1989) (29)
Hereditary amyloidosis in early childhood associated with a novel insertion-deletion (indel) in the fibrinogen Aalpha chain gene. (2005) (29)
A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis. (2011) (29)
Platelet glycoprotein IIIa Pl A polymorphism in young men with myocardial infarction (1996) (28)
Clinical, radiological and serum amyloid P component scintigraphic features of beta2-microglobulin amyloidosis associated with continuous ambulatory peritoneal dialysis. (1999) (28)
A prospective study of nutritional status in immunoglobulin light chain amyloidosis (2013) (28)
LL5beta is a phosphatidylinositol (3,4,5)-trisphosphate sensor that can bind the cytoskeletal adaptor, gamma-filamin. (2003) (28)
Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patients (2007) (27)
Deferred autologous stem cell transplantation in systemic AL amyloidosis (2018) (27)
Quantitative high-resolution microradiographic imaging of amyloid deposits in a novel murine model of AA amyloidosis (2005) (27)
Primary Localized Orbital Amyloidosis Composed of the Immunoglobulin γ Heavy Chain CH3 Domain (1994) (26)
Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors (2018) (26)
Differential cytokine secretion results from p65 and c-Rel NF-κB subunit signaling in peripheral blood mononuclear cells of TNF receptor-associated periodic syndrome patients. (2011) (26)
Profiling of phosphoinositide molecular species in human and mouse platelets identifies new species increasing following stimulation. (2018) (26)
Structural and Folding Dynamic Properties of the T70N Variant of Human Lysozyme* (2003) (26)
Analysis of the TTR gene in the investigation of amyloidosis: A 25‐year single UK center experience (2018) (25)
Laryngeal presentation of systemic apolipoprotein A‐I–derived amyloidosis (2009) (25)
From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature (2006) (25)
A simple assay method for determination of the specific radioactivity of the gamma-phosphate group of 32P-labelled ATP. (1983) (25)
Exploratory Study of MYD88 L265P, Rare NLRP3 Variants, and Clonal Hematopoiesis Prevalence in Patients With Schnitzler Syndrome (2019) (25)
Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment (2017) (24)
SGK1 Is a Critical Component of an AKT-Independent Pathway Essential for PI3K-Mediated Tumor Development and Maintenance. (2017) (24)
Identification of a novel inositol phosphate recognition site: specific [3H]inositol hexakisphosphate binding to brain regions and cerebellar membranes. (1990) (24)
Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis (2016) (24)
Scintigraphy with 123I-serum amyloid P component in Alzheimer disease. (1998) (24)
The Parkinson's disease gene PINK1 activates Akt via PINK1 kinase-dependent regulation of the phospholipid PI(3,4,5)P3 (2019) (24)
Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine. (2018) (23)
The Phosphoinositide 3-Kinase Isoform PI3Kβ Regulates Osteoclast-Mediated Bone Resorption in Humans and Mice (2014) (23)
Hereditary amyloidosis with progressive peripheral neuropathy associated with apolipoprotein AI Gly26Arg: Outcome of hepatorenal transplantation (2007) (23)
A heterotrimeric GTPase-regulated isoform of PI3K and the regulation of its potential effectors. (1996) (23)
Gi-mediated translocation of GLUT4 is independent of p85/p110α and p110γ phosphoinositide 3-kinases but might involve the activation of Akt kinase (2000) (23)
TNF Receptor Associated Periodic Syndrome associated with gonosomal mosaicism of a novel 24 nucleotide TNFRSF1A deletion (2016) (22)
Perturbations of PIP3 signalling trigger a global remodelling of mRNA landscape and reveal a transcriptional feedback loop (2015) (22)
The metabolism and functions of inositol pentakisphosphate and inositol hexakisphosphate. (1989) (22)
Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase g (2000) (22)
A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement (2018) (22)
Familial Mediterranean fever gene. (1998) (22)
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light‐chain amyloidosis (2020) (22)
Two types of amyloid in a single heart. (2014) (22)
Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance (2019) (22)
Familial amyloidotic polyneuropathy with severe renal involvement in association with transthyretin Gly47Glu in Dutch, British and American-Finnish families (2004) (22)
Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis (2018) (21)
Phosphoinositide 3-OH Kinase Regulates Integrin-Dependent Processes in Neutrophils by Signaling through Its Effector ARAP3 (2013) (21)
Renal Amyloidosis Associated With 5 Novel Variants in the Fibrinogen A Alpha Chain Protein (2016) (21)
Emerging treatments for amyloidosis. (2015) (21)
Hereditary fibrinogen A alpha-chain amyloidosis: clinical phenotype and role of liver transplantation. (2010) (21)
Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor. (2017) (21)
Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. (2021) (21)
A 24‐year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom (2019) (21)
Familial amyloid polyneuropathy associated with the novel transthyretin variant Arg34Gly (2012) (21)
3D time series analysis of cell shape using Laplacian approaches (2013) (21)
Cell biology: Moving in mysterious ways (2000) (21)
Oculoleptomeningeal Amyloidosis associated with transthyretin Leu12Pro in an African patient (2014) (21)
Intermediate Dose Intravenous Melphalan and Dexamethasone Treatment in 144 Patients with Systemic AL Amyloidosis. (2004) (20)
Activation of the neutrophil NADPH oxidase by Aspergillus fumigatus (2012) (20)
Amyloid persistence in decellularized liver: biochemical and histopathological characterization (2015) (20)
Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities (2019) (20)
Genome organization and chromatin analysis identify transcriptional downregulation of insulin-like growth factor signaling as a hallmark of aging in developing B cells (2018) (20)
The hexosamine biosynthesis pathway and O‐GlcNAcylation maintain insulin‐stimulated PI3K‐PKB phosphorylation and tumour cell growth after short‐term glucose deprivation (2014) (20)
Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy. (1996) (20)
In B cells, phosphatidylinositol 5-phosphate 4-kinase–α synthesizes PI(4,5)P2 to impact mTORC2 and Akt signaling (2016) (19)
Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis - Results From the UK Amyloidosis Treatment Trial (2009) (19)
Amyloid Typing: Experience from a Large Referral Centre (2012) (19)
A novel amyloidogenic transthyretin variant, Gly53Ala, associated with intermittent headaches and ataxia (2006) (19)
Production of inositol trisphosphates and inositol tetrakisphosphate in stimulated pancreatic islets. (1987) (19)
Assessment of Multivessel Coronary Artery Disease Using Cardiovascular Magnetic Resonance Pixelwise Quantitative Perfusion Mapping. (2020) (19)
Synthesis and biological evaluation of aPtdIns(3,4,5)P3 affinity matrix (2001) (19)
Diagnosis and treatment of amyloidosis (1997) (18)
Amyloid and the GI tract (2009) (18)
The Diagnosis, Natural History and Treatment of Amyloidosis (1997) (18)
Afro-Caribbean Heart Failure in the United KingdomCLINICAL PERSPECTIVE (2016) (18)
Investigating the effect of arachidonate supplementation on the phosphoinositide content of MCF10a breast epithelial cells (2016) (18)
Class IA PI3Ks regulate subcellular and functional dynamics of IDO1 (2020) (18)
Changes in inositol lipids and phosphates after stimulation of the MAS-transfected NG115-401L-C3 cell line by mitogenic and non-mitogenic stimuli. (1990) (18)
99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis (2021) (18)
A specific nanobody prevents amyloidogenesis of D76N β2-microglobulin in vitro and modifies its tissue distribution in vivo (2017) (18)
Novel Pharmacological Strategies in Amyloidosis (2003) (17)
Hereditary amyloidosis caused by R554L fibrinogen Aα-chain mutation in a Spanish family and review of the literature (2013) (17)
Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis - a Matched Case Control Study (2015) (17)
Diagnostic amyloid proteomics: experience of the UK National Amyloidosis Centre (2020) (17)
Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage (2020) (17)
Immunoparesis defined by heavy+light chain suppression is a novel marker of long‐term outcomes in cardiac AL amyloidosis (2017) (17)
The Inositol-3-Phosphate Synthase Biosynthetic Enzyme Has Distinct Catalytic and Metabolic Roles (2016) (16)
Determination of the steady-state turnover rates of the metabolically active pools of phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate in human erythrocytes. (1989) (16)
Renal transplantation for amyloid end-stage renal failure-insights from serial serum amyloid P component scintigraphy (2000) (16)
Cardiac Magnetic Resonance–Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid (2021) (15)
Identifying Cardiac Amyloid in Aortic Stenosis: ECV Quantification by CT in TAVR Patients (2020) (15)
A novel variant of human lysozyme (T70N) is common in the normal population. (2000) (15)
Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation (2009) (15)
Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting (2014) (15)
Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis (2015) (14)
Is vasopressin-stimulated inositol lipid breakdown intrinsic to the mechanism of Ca2+-mobilization at V1 vasopressin receptors? (1983) (14)
Insulin and ATP stimulate actin polymerization in U937 cells by a wortmannin‐sensitive mechanism (1996) (14)
New and developing therapies for AL amyloidosis (2017) (14)
Signaling via Class IA Phosphoinositide 3-Kinases (PI3K) in Human, Breast-Derived Cell Lines (2013) (14)
A novel variant of human lysozyme (T70N) is common in the normal population (2000) (14)
Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology (2017) (14)
Structural determinants of LL5beta subcellular localisation and association with filamin C. (2007) (14)
Renal transplant outcomes in amyloidosis. (2021) (13)
CD 18-dependent activation of the neutrophil NADPH oxidase during phagocytosis of Escherichia coli or Staphylococcus aureus is regulated by class III but not class I or II PI 3 Ks (2008) (13)
Acute renal failure and nephrotic range proteinuria due to amyloidosis in an HIV-infected patient. (2006) (13)
Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1 (2018) (13)
Gβγ is a direct regulator of endogenous p101/p110γ and p84/p110γ PI3Kγ complexes in mouse neutrophils (2020) (13)
A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis (2010) (13)
ALchemy - A Large Prospective ‘Real World' Study of Chemotherapy in AL Amyloidosis (2011) (13)
V122I transthyretin variant in elderly black Americans. (2015) (13)
Hereditary amyloidosis [2] (multiple letters) (2002) (13)
Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies (2017) (13)
A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis (2019) (13)
Transient Post Chemotherapy Rise in NT Pro-BNP in AL Amyloidosis : Implications for Organ Response Assessment. (2009) (13)
Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis. (2014) (12)
Frontline Science: TNF‐α and GM‐CSF1 priming augments the role of SOS1/2 in driving activation of Ras, PI3K‐γ, and neutrophil proinflammatory responses (2019) (12)
Proteomic Analysis for the Diagnosis of Fibrinogen Aα-chain Amyloidosis (2019) (12)
Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance (2019) (12)
Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry (2013) (12)
Apolipoprotein E4 genotype is not a risk factor for systemic AA amyloidosis or familial amyloid polyneuropathy (1995) (12)
European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease (2011) (12)
AL and ATTR cardiac amyloid are different: native T1 mapping and ECV detect different biology (2014) (12)
Efficacy and Safety of Bortezomib in Systemic AL Amyloidosis - A Preliminary Report. (2006) (12)
Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers (2019) (12)
Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis (2008) (12)
Life-saving implantable cardioverter defibrillator therapy in cardiac AL amyloidosis (2014) (12)
Characteristic and Clinical Outcome of 340 Patients with Systemic AA Amyloidosis (2004) (12)
Signalling via class IA PI3Ks. (2011) (11)
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib (2021) (11)
TRAP1 chaperone protein mutations and autoinflammation (2019) (11)
AL kappa amyloid in a solitary extradural lymphoma. (1994) (11)
Studies of the structure and binding properties of hamster female protein. (1993) (11)
Advances in Biological Regulation (2016) (11)
Systemic AL (light-chain) amyloidosis and the gastrointestinal tract (2009) (11)
Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis (2020) (11)
British kindred with dominant FMF associated with high incidence of AA amyloidosis caused by novel MEFV variant, and a review of the literature. (2019) (11)
A case report in cardiovascular magnetic resonance: the contrast agent matters in amyloid (2017) (10)
In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment. (2009) (10)
A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort (2014) (10)
The role of PBSCT in treatment of AL amyloidosis is far from settled. (2004) (10)
Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria (2019) (10)
Mechanism of the regulation of type IB phosphoinositide 3 OH-kinase by G-protein βγ subunits (10)
Purification of ARAP3 and characterization of GAP activities. (2006) (10)
Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis (2015) (10)
INSAID variant classification and Eurofever criteria guide optimal treatment strategy in patients with TRAPS: data from the Eurofever registry. (2020) (9)
3 New amyloidogenic TTR mutations: Pro12, Glu18, and Val33 (1996) (9)
Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis (2008) (9)
Human plasma ﬁbrinogen is synthesized in the liver (2007) (9)
Echocardiographic assessment of cardiac involvement in systemic AL amyloidosis in relation to whole body amyloid load measured by serum amyloid P component (SAP) clearance. (1997) (9)
Primary localized orbital amyloidosis composed of the immunoglobulin gamma heavy chain CH3 domain. (1994) (9)
Localizing the lipid products of PI3Kγ in neutrophils (2016) (9)
Extracellular volume with bolus‐only technique in amyloidosis patients: Diagnostic accuracy, correlation with other clinical cardiac measures, and ability to track changes in amyloid load over time (2018) (9)
The value of screening biopsies in light chain (AL) and transthyretin (ATTR) amyloidosis. (2020) (8)
Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry (2020) (8)
Vitreous amyloidosis in alanine 71 transthyretin mutation (2005) (8)
An unusual phenotype in Muckle-Wells syndrome associated with NLRP3 E311K. (2011) (8)
UK experience of liver transplantation in FAP (1996) (8)
The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis (2020) (8)
Amyloid cardiomyopathy associated with a novel apolipoprotein A–I Q172P variant (2015) (8)
The liver in systemic amyloidosis: Insights from I-123-serum amyloid P component scintigraphy (1997) (8)
DPD Scintigraphy for diagnosis of amyloidosis in 1191 patients– a single centre experience (2015) (8)
Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment (2022) (8)
Generalized Amyloidosis in an Eastern Bongo (Tragelaphus eurycerus isaaci) (2011) (8)
Kinase-independent synthesis of 3-phosphorylated phosphoinositides by a phosphotransferase (2022) (8)
Comparison of Free Light Chain Assays: Freelite and N Latex in Diagnosis, Monitoring, and Predicting Survival in Light Chain Amyloidosis. (2016) (8)
One Hundred Cases of Localized Laryngeal Amyloidosis ‐ Evidence for Future Management (2021) (8)
Staging Cardiac Amyloidosis With CMR: Understanding the Different Phenotypes. (2016) (7)
Quantitative cardiovascular magnetic resonance myocardial perfusion mapping to assess hyperaemic response to adenosine stress. (2020) (7)
Corrigendum: Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kγ (2003) (7)
A PHASE 2, MULTI-CENTER, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND EXPLORATORY CLINICAL ACTIVITY OF ALN-TTRSC, AN RNAI THERAPEUTIC FOR THE TREATMENT OF PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS (2015) (7)
Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis (2022) (7)
Occult adrenal insufficiency secondary to amyloidosis in the context of chronic renal failure. (1995) (7)
Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis (2021) (7)
001 Multiparametric mapping to understand pathophysiology in cardiac amyloidosis (2017) (7)
Usefulness of Tc-99m-DPD scintigraphy in cardiac amyloidosis - Reply (2008) (7)
Monitoring systemic amyloidosis using MRI measurements of the extracellular volume fraction (2013) (7)
Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis (2022) (7)
Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis (2012) (7)
Synthesis of dipalmitoyl phosphatidylinositol 3,4-bis(phosphate)and 3,4,5-tris(phosphate) and their enantiomers (1997) (7)
Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts (2017) (7)
Cardiac computed tomography for the detection of cardiac amyloidosis. (2017) (6)
Receptor and G-protein-dependent regulation of turkey erythrocyte phosphoinositidase C. (1988) (6)
Unifocal amyloidosis: a rare cause of spinal cord compression (2002) (6)
Stimulation of phosphatidylinositol-3-kinase by insulin-like growth factor 1 and other agonists. (1992) (6)
SYSTEMATIC REVIEW OF 1142 ADMISSIONS WITH ACUTE HEART FAILURE REVEALS HIGH FREQUENCY OF TRANSTHYRETIN V122I CARDIAC AMYLOIDOSIS IN AFRO-CARIBBEAN PATIENTS (2012) (6)
Gi-mediated translocation of GLUT4 is independent of p85/p110alpha and p110gamma phosphoinositide 3-kinases but might involve the activation of Akt kinase. (2000) (6)
Characterisation and management of vitreous and nerve amyloid in familial amyloid polyneuropathy due to variant transthyretin, Phe33Val (2007) (6)
LGE-PSIR is an independent predictor of mortality in cardiac amyloidosis: a 250 patient prospective study (2015) (6)
Measurement of the metabolic turnover of the 4- and 5-phosphates of phosphatidylinositol 4,5-bisphosphate in erythrocytes (1982) (6)
GPCR activation of Ras and PI 3 K c in neutrophils depends on PLC b 2 / b 3 and the RasGEF RasGRP (2013) (6)
Quality of life in ATTR amyloidosis (2015) (6)
Diflunisal therapy for cardiac ATTR amyloidosis: a longitudinal, prospective, single centre study (2015) (6)
Misdiagnosing renal amyloidosis as minimal change disease. (2014) (6)
A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP. (2009) (6)
PI3Kδ Forms Distinct Multiprotein Complexes at the TCR Signalosome in Naïve and Differentiated CD4+ T Cells (2021) (6)
Carpal Tunnel Biopsy Identifying Transthyretin Amyloidosis (2017) (5)
More Paths to PI3Kγ (2013) (5)
Two types of systemic amyloidosis in a single patient (2020) (5)
AL amyloidosis Sequential heart and autologous stem cell transplantation for systemic (2013) (5)
Hereditary Renal Amyloidosis in a German Family Associated with Fibrinogen A _ Chain Glu540Val (2004) (5)
Equilibrium contrast CMR for the detection of amyloidosis in mice (2011) (5)
Inositol hexakisphosphate biosynthesis in mammalian brain: identification of a novel inositol pentakisphosphate kinase. (1990) (5)
Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome (2019) (5)
Impact of afterload and infiltration on coexisting aortic stenosis and transthyretin amyloidosis (2021) (5)
Extracellular Volume Fraction by Computed Tomography Predicts Long-Term Prognosis Among Patients With Cardiac Amyloidosis. (2022) (5)
Pre-contrast ShMOLLI T1 mapping in cardiac AL amyloidosis (2012) (5)
Use Of Plasma Cell Immunophenotype As Prognostic Markers In Patients With Systemic AL Amyloidosis (2013) (5)
Oligonucleotide Drugs for Transthyretin Amyloidosis. (2018) (5)
Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years (2022) (5)
Response to Letters Regarding Article, "Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis". (2016) (5)
ALN-TTR, an RNAI therapeutic for the treatment of transthyretin amyloidosis (2011) (5)
Recognising and understanding cryopyrin-associated periodic syndrome in adults. (2019) (5)
SAT0010 A Targeted Next-Generation Sequencing Gene Panel for Autoinflammation (2016) (5)
Clinical characteristics and SAP scintigraphic findings in 10 patients with AGel amyloidosis (2014) (5)
Inositol phospholipids and phosphates for investigation of intact cell phospholipase C substrates and products. (1991) (5)
Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry (2021) (5)
Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK (2022) (5)
Fast random walker for neutrophil cell segmentation in 3D (2012) (5)
Differential cytokine secretion resulting from p65 and c-Rel NF-kappaB subunit signaling in peripheral blood mononuclear cells of TNFR-associated periodic fever syndrome patients (2011) (4)
Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic AL amyloidosis (2018) (4)
Myocardial Fibrosis Quantified by Cardiac CT Predicts Outcome in Severe Aortic Stenosis After Transcatheter Intervention (2021) (4)
CD18-dependent activation of the neutrophil NADPH oxidase during phagocytosis of E.coli or S.aureus is regulated by Class III but not Class I or II PI3Ks (2008) (4)
168 Structural analysis of a novel isoform of phosphoinositide 30H-kinase (1997) (4)
Search for AL amyloidosis risk factors using Mendelian randomization. (2021) (4)
A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred (2015) (4)
Acyl chain selection couples the consumption and synthesis of phosphoinositides (2022) (4)
Receptor regulation of phosphoinositide 3-hydroxykinase in the NG115-401L-C3 neuronal cell line: stimulation by insulin-like growth factor-I. (1993) (4)
Amyloidosis Diagnosed in Solid Organ Transplant Recipients (2020) (4)
CD18-dependent activation of the neutrophil NADPH oxidase during phagocytosis of E.coli or S.aureus is regulated by Class III but not Class I or II PI3Ks (2008) (4)
028 Routine identification of hypoperfusion in cardiac amyloidosis by myocardial blood flow mapping (2017) (4)
48Quantification of myocardial infarct size and microvascular obstruction using dark-blood late gadolinium enhancement (2019) (4)
Prevalence, characteristics and outcomes of older patients with hereditary versus wild‐type transthyretin amyloid cardiomyopathy (2023) (4)
Role of heart transplantation in systemic amyloidosis. (1996) (4)
Prognostic importance of the 6 min walk test in light chain (AL) amyloidosis (2022) (4)
Achieving a Difference in Involved and Uninvolved Light Chains (dFLC) of Less Than 10mg/L Is the New Goal of Therapy in Systemic AL Amyloidosis: Analysis of 916 Patients Treated Upfront with Bortezomib-Based Therapy (2018) (4)
Early‐onset urticaria: a marker of cryopyrin‐associated periodic syndrome (2017) (4)
Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP) (2015) (4)
A New Deletion Mutation of the Apolipoprotein Ai Gene Causing Hereditary Amyloidosis (1996) (4)
Exome Sequencing To Define A Genetic Signature Of Plasma Cells In Systemic AL Amyloidosis (2013) (4)
SAP Scintigraphy in 43 patients with TTR-associated FAP (1996) (4)
Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy (2021) (4)
Six-minute walk test (6MWT) in AL amyloidosis – baseline and 12-month follow-up after chemotherapy (2017) (4)
Acute hepatitis in a child heterozygous for the I259V MEFV gene variant. (2014) (4)
Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first‐line treatment of systemic light chain amyloidosis in the UK (2021) (3)
Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) for the Treatment of Systemic AL Amyloidosis: Long Term Outcomes among 202 Patients (2008) (3)
Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real‐world longitudinal data (2021) (3)
1 A multi-centre study of cardiac amyloidosis in tavi patients (2018) (3)
Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two (2017) (3)
Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two (2017) (3)
Systemic amyloidosis: getting to the heart of the matter. (2010) (3)
Transthyretin Ile84Thr is associated with familial amyloid polyneuropathy (2000) (3)
Role of 99mTc‐DPD scintigraphy in imaging extra‐cardiac light chain (AL) amyloidosis (2018) (3)
Interim analysis of ALCHemy – a prospective study of 1000 patients with Systemic AL amyloidosis (2015) (3)
Analysis of Cardiac Amyloidosis Progression Using Model-Based Markers (2020) (3)
N-terminal fragment of brain natriuretic peptide (NT-ProBNP) - a new response criterion in AL amyloidosis (2010) (3)
Bleeding symptoms and coagulation test abnormalities in 308 patients with AL amyloidosis (1999) (3)
AL amyloidosis: new drugs and tests, but old challenges. (2012) (3)
A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis. (2012) (3)
Monday, 27 August 2012 (2012) (3)
The role of serial 99mTc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis (2021) (3)
Challenges of Using NT-Probnp for Response Assessment in Systemic AL Amyloidosis - Analysis of a Prospective Study (2016) (3)
The role of renal transplantation in systemic AL amyloidosis. (2005) (3)
Erratum: Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kγ (Nature (2000) 406 (897-902)) (2003) (3)
Local Shape Representation in 3D: from Weighted Spherical Harmonics to Spherical Wavelet (2012) (3)
Biochemical basis of the amyloid diseases. (2010) (3)
Modulation of Monomeric G Proteins by Phosphoinositides (2010) (3)
High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study. (2017) (3)
The Phosphoinositide 3-Kinase Isoform PI 3 K Regulates Osteoclast-Mediated Bone Resorption in Humans and Mice (2014) (3)
N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T hold diagnostic value in cardiac amyloidosis (2023) (3)
Nephrotic Syndrome as a Presenting Feature in a Child With NLRP3 Mutation. (2018) (3)
A novel complex indel mutation in the fibrinogen aβ chain gene in an asian child with systemic amyloidosis (2004) (3)
Liver Transplantation in ATTR Met30 and Other Variants: Time to Shift the Paradigm? (2004) (3)
The Prognostic Importance of the 6-Minute Walk Test in AL Amyloidosis (2020) (3)
Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis (2019) (2)
A Novel Mass Spectrometry Method to Identify the Serum Monoclonal Light Chain Component and Infer Organ Involvement in Systemic Light Chain Amyloidosis (2018) (2)
24Amyloid-AS: detecting occult Cardiac Amyloid during TAVI work-up Computed Tomography (2019) (2)
Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis (2013) (2)
The Prognostic Significance of Phenotypically ‘Normal’ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma (2014) (2)
Abstract 14407: Regression of Cardiac AL Amyloid by Cardiovascular Magnetic Resonance (2016) (2)
Inositol hexakisphosphate-membranes interactions: the role of metal ions. (1991) (2)
Multi-Imaging Characterization of Cardiac Phenotype in Different Types of Amyloidosis. (2022) (2)
A UK consensus algorithm for early treatment modification in newly diagnosed systemic light‐chain amyloidosis (2022) (2)
Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years (2013) (2)
Cardiac amyloid burden assessment by T1 mapping predicts survival in patients with systemic AL amyloidosis - a 2 year follow-up study (2014) (2)
Cardiac involvement in cardiac AL amyloidosis as measured by equilibrium contrast cardiovascular magnetic resonance (2012) (2)
Scintigraphic Imaging of Amyloidosis with 123Iodine Serum Amyloid P Component (1991) (2)
DIFFERENTIATING HYPERTENSIVE HEART DISEASE AND CARDIAC TRANSTHYRETIN ISOLEUCINE 122 (V122I) AMYLOIDOSIS IN AFRO-CARIBBEAN PATIENTS (2012) (2)
The UK National Amyloidosis Centre. (2019) (2)
INVIVO TURNOVER STUDIES OF RADIOIODINATED C-REACTIVE PROTEIN IN MAN (1992) (2)
PATTERNS OF LATE GADOLINIUM ENHANCEMENT PREDICT SURVIVAL IN CARDIAC AMYLOIDOSIS: A SYSTEMATIC REVIEW OF 95 CASES WITH AL OR TTR TYPE (2012) (2)
Pitfalls in conducting prospective trials in stage III cardiac amyloidosis – experience from the REVEAL study (2017) (2)
Phosphodiesterase-catalysed breakdown of phosphatidylinositol 4,5-bisphosphate initiates receptor-stimulated inositol lipid metabolism (1984) (2)
Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis (2021) (2)
Identifying Mixed Phenotype: Evaluating the Presence of Polyneuropathy in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Cardiomyopathy (2019) (2)
Early Detection of Cardiac Systolic Functional Impairment and Correlation with NT-ProBNP Change in AL Amyloidosis by Cardiac Lateral Wall Tissue Doppler S Wave (2009) (2)
Erratum: Evaluation and management of the cardiac amyloidosis (Journal of the American College of Cardiology (2007) 50: (2101-2110)) (2011) (2)
Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis (2012) (2)
Native T1 mapping in ATTR cardiac amyloidosis - comparison with AL cardiac amyloidosis - a 200 patient study (2014) (2)
Multiorgan ECV as measured by EQ-MRI in systemic amyloidosis (2013) (2)
3 year follow-up results on a treatment for amyloid A (AA) amyloidosis: Efficacy and safety of eprodisate (NC-503; 1,3-propanedisulfonate), the first of a new class of anti-amyloid compounds. (2006) (2)
Impact of Chromosomal Abnormalities Revealed by Interphase FISH on Survival in Primary Light Chain Amyloidosis. (2004) (2)
A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year (2017) (2)
Amyloidosis, not myeloma (2005) (2)
Characteristics and natural history of early-stage cardiac transthyretin amyloidosis (2022) (2)
Urinary retinol binding protein predicts renal outcome in systemic immunoglobulin light‐chain (AL) amyloidosis (2021) (2)
Efficacy and Safety of Canakinumab (ACZ885), a Fully Human Anti-Interleukin-1b-Antibody, in Cryopyrin Associated Periodic Fever Syndrome Results of a Multicenter, Randomized, Double-blind, Phase III Study (2009) (2)
Thalidomide Treatment in 80 Patients with AL Amyloidosis: Tolerability, Clonal Disease Response and Clinical Outcome (2004) (2)
Reply: Amyloidosis in the Era of Mass Spectrometry-Based Proteomics. (2018) (2)
Analysis of disease progression in patients with transthyretin cardiac amyloidosis (2015) (2)
Chapter 133 Amyloidosis of the Skin (2010) (1)
The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis (2020) (1)
Transthyretin-related familial amyloid polyneuropathy (ATTR-FAP) in Poland - genetic and clinical presentation. (2020) (1)
PI3K regulates integrin-dependent processes in neutrophils by signalling through its effector ARAP3 (2013) (1)
PS1373 A TWENTY-FOUR YEAR EXPERIENCE OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LIGHT CHAIN AMYLOIDOSIS PATIENTS IN THE UNITED KINGDOM (2019) (1)
Imaging amyloidosis in Still's disease. (1989) (1)
Reply to S. Girnius et al. (2013) (1)
The role of somatic NLRP3 mosaicism and new gene discovery in mutation negative cryopyrin-associated periodic syndrome patients (2014) (1)
High yield of cardiac MRI in the investigation of elderly heart failure patients of African descent (2013) (1)
Treatment for amyloid A (AA) amyloidosis with eprodisate disodium (NC-503): 2-year results of efficacy and safety from a multi-center international trial (2006) (1)
Metabolism of myo-inositol pentakisphosphates in mammalian brain. (1992) (1)
Identification of a novel monogenic autoinflammatory disease due to mutation in a mitochondrial chaperone protein in a single kindred, and cure with allogeneic haematopoietic stem cell transplantation (2014) (1)
Serum Amyloid P Component: A Specific Molecular Targeting Vehicle in Amyloidosis (1989) (1)
19 Myocardial perfusion mapping in cardiac amyloidosis- unearthing the spectrum from infiltration to ischaemia (2019) (1)
Abstract 19388: Cardiovascular Magnetic Resonance in Cardiac Amyloidosis: A 242 Patient Prospective Study (2014) (1)
The effect of a novel phosphoinositide 3-kinase δ inhibitor (PI3Kδ), GSK2269557, on potential biomarkers measured from the lungs of healthy male smokers (2013) (1)
The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre (2022) (1)
The phenotype of patients with cryopyrin-associated periodic syndrome and response to treatment with anti-interleukin 1 (anakinira) (2006) (1)
Interstitial expansion in health and disease - an equilibrium contrast CMR study (2012) (1)
A Micro-SPECT/CT System for Imaging of AA-Amyloidosis in Mice (2005) (1)
Ixazomib, lenalidomide and dexamethasone in relapsed AL amyloidosis – a first report (2019) (1)
Beneficial effect of eprodisate (NC-503) on the preservation of kidney function in AA amyloidosis patients : 3-year follow-up results (2007) (1)
The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis (2020) (1)
Chapter 21 Amyloidosis (2008) (1)
Occult senile cardiac amyloid in severe calcific aortic stenosis is not rare and has a poor prognosis: a 146 patient CMR biopsy study (2016) (1)
Gi-mediated translocation of GLUT 4 is independent of p 85 / p 110 α and p 110 γ phosphoinositide 3-kinases but might involve the activation of Akt kinase (1)
Hyperimmunoglobulin D syndrome in an Indian family undiagnosed for 11 years (2017) (1)
210 Retrospective Analysis of Adult Referrals to the Periodic Fever Service at the National Amyloidosis Centre: Increasing Recognition of Adult-Onset Genetic Autoinflammatory Disease (2016) (1)
Controllable expression of SAA in transgenic mice: a refined model of systemic amyloidosis (2010) (1)
Diagnostic pitfalls and treatment in a young man with systemic amyloidosis (1996) (1)
Bleeding diathesis and prothrombotic tendencies in patients with newly diagnosed systemic light chain Amyloidosis: important clinical implications (2015) (1)
Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival, (2011) (1)
Abnormal NT-ProBNP in AL Amyloidosis Patients without Cardiac Involvement at Diagnosis - A Predictor of Subsequent Cardiac Involvement. (2007) (1)
T1 mapping for myocardial extracellular volume measurement by cardiovascular magnetic resonance: bolus only vs primed infusion technique (2013) (1)
Phosphoinositide 3OH Kinase Regulates Integrin-Dependent Processes in Neutrophils by Signaling through Its Effector ARAP 3 (2013) (1)
NT-proBNP and High-Sensitivity Troponin T Hold Diagnostic Value in Cardiac Amyloidosis. (2022) (1)
3D time series analysis of cell shape using Laplacian approaches (2013) (1)
Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis. (2023) (1)
CHAPTER 155 – Modulation of Monomeric G Proteins by Phosphoinositides (2003) (1)
A faint in the emergency department (due to primary systemic amyloidosis neuropathy). (2004) (1)
Genome organization and chromatin analysis identify transcriptional downregulation of insulin-like growth factor signaling as a hallmark of aging in developing B cells (2018) (1)
Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis (2022) (1)
Scintigraphic imaging and turnover studies with (131) I-serum amyloid P component (SAP) in systemic amyloidosis (1999) (1)
More Paths to PI3Kc (2013) (1)
Splenic regression of amyloid on multi-modality imaging in response to treatment with patisiran and diflunisal in hereditary transthyretin amyloidosis (2021) (1)
Metabolic pooling of inositol lipids in mature erythrocytes and in hormone-stimulated mammalian cells. (1987) (1)
Chapter 42. Amyloidosis (2007) (1)
Structural analysis of a novel isoform of phosphoinositide 3OH-kinase. (1997) (1)
Abstract 16030: Heterogeneity of Electrocardiographic Findings in Cardiac Transthyretin (ATTR) Amyloidosis and Impact on Survival (2014) (1)
Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis (2013) (1)
A Prospective Study of Treatment Outcomes in 179 Patients with Advanced Cardiac Stage STAGE IIIb Amyloidosis (2015) (1)
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Commentary (2007) (1)
General Synthesis of 3‐Phosphorylated myo‐Inositol Phospholipids and Derivatives. (1999) (1)
Five novel TTR variants: associated phenotypes and structural consequences (2015) (1)
Abstract 15710: Myocardial Ischaemia in Cardiac Amyloidosis, Changing Perspectives (2020) (1)
Intermittent Loss of Second Heart Sound (2006) (1)
Letter by Treibel et al Regarding Article, "Sex-Related Discordance Between Aortic Valve Calcification and Hemodynamic Severity of Aortic Stenosis: Is Valvular Fibrosis the Explanation?" (2017) (1)
237SUV Quantification in DPD Scintigraphy (2019) (1)
Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis. (2012) (1)
Resource Phosphoproteomic Analys es of Interleukin 2 Signaling Reveal Integrated JAK Kinase-Dependent and-Independent Networks in CD 8 + T Cells Graphical Abstract Highlights (2016) (1)
Safety and Efficacy of Canakinumab in Patients with Caps: Interim Results from the Beta-confident Registry (2018) (1)
Clinical ApoA‐IV amyloid is associated with fibrillogenic signal sequence (2021) (1)
Moderated Poster Session 4: Monday 4 May 2015, 15:30-16:30Room: Moderated Poster Area. (2015) (1)
Imaging Hereditary Amyloidosis of Ostertag (1991) (1)
Longterm Outcomes and Improved Renal Function with Autologous Stem Cell Transplantation (ASCT) in Light Chain Deposition Disease (LCDD) (2014) (1)
nondiagnostic in AL, and DNA studies are often required to further exclude hereditary forms of amyloidosis (3). (2006) (0)
prolonged progression-free survival amyloidosis is associated with high clonal response rates and Cyclophosphamide, bortezomib, and dexamethasone therapy in AL (2012) (0)
The Authors Reply. (2021) (0)
Comparison of Different Technetium-99m-Labeled Bone Tracers for Imaging Cardiac Amyloidosis. (2022) (0)
Heterogeneity Amongst Myo-Inositol Derivatives: Metabolism of Second Messengers and Synthesis of Co-Signals (1990) (0)
Assessment of multi-vessel coronary artery disease using cardiovascular magnetic resonance pixelwise quantitative perfusion mapping Brief Title: CMR perfusion mapping for assessment multi-vessel coronary disease (2020) (0)
Pathophysiology and treatment of systemic (2013) (0)
The roles of PI3Ks in cellular regulation (1997) (0)
Scintigraphic Imaging of Amyloid Deposits Using Technetium-Labelled Serum Amyloid P Component (1996) (0)
by Signaling through Its Effector ARAP3 Integrin-Dependent Processes in Neutrophils Phosphoinositide 3-OH Kinase Regulates (2012) (0)
Length of Hospital Stay is an Independent Predictor of Overall Survival in Patients with systemic AL Amyloidosis (2017) (0)
Whole Exome Sequencing reveals a NLRP3 mutation in exon 5 in a patient with CINCA (2015) (0)
to distribute methods and multi-functional device and circulate liquids in casings (1997) (0)
Measurement of Serum Free Light Chains in AL Amyloidosis (2004) (0)
ADMISSIONS WITH ACUTE HEART FAILURE REVEALS HIGH FREQUENCY OF TRANSTHYRETIN V 122 I CARDIAC AMYLOIDOSIS IN AFRO-CARIBBEAN PATIENTS (2012) (0)
Compounds that inhibit binding of SAP to treat osteoarthritis. (2004) (0)
TTR mutations in 2 patients wtph a clinical diagnosis of senile cardiac amyloidosis (1996) (0)
P119Oedema in amyloidosis: more than meets the eye (2019) (0)
Faculty Opinions recommendation of Positional identification of Ncf1 as a gene that regulates arthritis severity in rats. (2002) (0)
The LCLAT1/LYCAT acyltransferase supports EGF-mediated phosphatidylinositol-3,4,5-trisphosphate and Akt signaling (2023) (0)
P176Fat water gadolinium enhancement imaging in myocarditis: shifting the goalpost (2019) (0)
of liver transplantation -chain amyloidosis: clinical phenotype and role α Hereditary fibrinogen A (2013) (0)
Impact of fibrillex, an anti-amyloid product, on amyloid A (AA) protein content in abdominal fat tissue biopsies from patients with AA amyloidosis : Results from a pivotal international trial (2005) (0)
Table of Contents (1993) (0)
Clinical Profiles and Outcomes in 1203 Newly Diagnosed Patients With Systemic AL Amyloidosis – First Analysis of the ALChemy Study. (2017) (0)
Is Serum Amyloid P Component Required for in Vivo Amyloid Deposition (1996) (0)
The synthetic TRPML1 agonist, ML-SA1, rescues Alzheimer-related alterations of the endosomal-autophagic-lysosomal system. (2023) (0)
Loss of function mutation in a mitochondrial chaperone protein leading to dyregulated ROS production, and autoinflammatory disease in a single kindred (2015) (0)
Is There a Role for Thalidomide Maintenance in the Treatment of AL Amyloidosis (2009) (0)
Biological studies of serum amyloid P component : a specific targeting vehicle in amyloidosis (1991) (0)
Title : Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology Running head : Anakinra in AA amyloidosis of uncertain aetiology (2017) (0)
FRI0457 LONG-TERM OUTCOMES AND TREATMENT EFFICACY IN PATIENTS WITH TNF RECEPTOR-ASSOCIATED AUTOINFLAMMATORY SYNDROME (TRAPS) FROM THE EUROFEVER INTERNATIONAL REGISTRY (2020) (0)
Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance (2019) (0)
Treatment of renal amyloidosis in rheumatoid arthritis requires further investigation: comment on the case report by Elkayam et al - Reply (2003) (0)
12Cardiac amyloid in TAVI Patients - bystander or disease modifier? (2019) (0)
736 β2 integrin-dependent activation of NOX2 oxidase in wound macrophages is required for physiological wound healing (2016) (0)
303Quantitative CMR perfusion mapping to detect microvascular dysfunction in patients without obstructive coronary disease (2019) (0)
treatment outcome AL amyloidosis associated with IgM paraproteinaemia - clinical profile and (2013) (0)
Title: Changing Epidemiology of AA Amyloidosis – Clinical Observations Over 25 Years at a Single National Referral Centre Running head: Changing Epidemiology of AA Amyloidosis Key words: AA amyloidosis, Rheumatoid arthritis, Juvenile idiopathic arthritis, Systemic autoinflammatory disorders, Biologi (2018) (0)
Faculty Opinions recommendation of Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. (2005) (0)
Structure of Lipid Kinase p110b/p85b Elucidates anUnusualSH2-Domain-MediatedInhibitoryMechanism (0)
Thesis Reports (2002) (0)
Autologous Stem Cell Transplantation in AL-Amyloidosis Following Yttrium-90 Labelled Anti-CD66 Monoclonal Antibody As Sole Conditioning Is Associated with Low Toxicity and Demonstrable Disease Responses (2021) (0)
Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR) (2020) (0)
Flow processes at an open channel junction (2006) (0)
008 Demonstration of cardiac AL amyloidosis regression after succesful chemotherapy. a CMR study (2017) (0)
Tc-99m-3,3-Diphosphono-1,2-Propanodicarboxylic Acid (Tc-99m DPD) scintigraphy - a novel imaging modality for systemic amyloidosis (2011) (0)
Deferred autologous stem cell transplantation in systemic AL amyloidosis (2018) (0)
302Redefining assessment of adenosine stress response using CMR perfusion mapping: An alternative to splenic switch off (2019) (0)
Global longitudinal strain predicts survival and response in patients with systemic AL amyloidosis. analysis of 915 patients from the ALchemy prospective trial (2020) (0)
Complexes PI 3 K { beta } Plays a Critical Role in Neutrophil Activation by Immune ` (2011) (0)
Efficacy and Safety of Canakinumab in a Large Cohort of Cryopyrin-Associated Periodic Syndrome (CAPS) Patients across All Severity Phenotypes (2011) (0)
Frequency of Hereditary Systemic Amyloidosis among Patients with Apparent Primary Al Type (2002) (0)
FRI0618 ANALYSIS OF NEW REFERRALS TO A SPECIALIST UK ADULT AUTOINFLAMMATORY DISEASE SERVICE (2019) (0)
Clinical Features, Diagnosis and Treatment of Familial Amyloid Polyneuropathy (1996) (0)
Comparison of gadolinium-enhanced cardiac MRI with endomyocardial biopsy for detection of cardiac amyloidosis (2012) (0)
Natural History and Regression of Amyloidosis Demonstrated by Serum Amyloid P Component Scintigraphy (1993) (0)
093 Cardiac involvement in cardiac al amyloidosis as measured by equilibrium contrast cardiovascular magnetic resonance (2012) (0)
Panda eyes and heart failure. (2005) (0)
The V122I Variant in Hereditary Transthyretin-Mediated Amyloidosis is Significantly Associated with Polyneuropathy (2020) (0)
Title: Immunoparesis defined by heavy+light chain suppression is a novel marker of long- term outcomes in cardiac AL amyloidosis Running title: HLC suppression in AL amyloidosis Authors and affiliations: (2018) (0)
Hepatic Amyloidosis in a Chronically Entangled Grey Seal (Halichoerus grypus). (2022) (0)
Spotting senile systemic amyloidosis: why we miss it (2015) (0)
3 Treatment response in cardiac al amyloidosis assessed by CMR: findings at 3 months, 6 months and 1 year post-chemotherapy (2018) (0)
A Primed State Exists in vivo Following Regression of Murine AA Amyloidosis (1991) (0)
HETEROGENEITY AMONGST PATIENTS WITH CHRONIC INFANTILE NEUROLOGICAL CUTANEOUS AND ARTICULAR (CINCA) SYNDROME (2004) (0)
3 The detection of cardiac amyloidosis using extracellular volume quantification by computed tomography (2018) (0)
Transthyretin Glu18, A New Variant Associated With Familial Amyloid Polyneuropathy (1998) (0)
Faculty of 1000 evaluation for Tumor suppressor PTEN mediates sensing of chemoattractant gradients. (2012) (0)
Muckle-Wells syndrome: a novel presentation (2016) (0)
DETERMINING THE ELECTROCARDIOGRAPHIC FEATURES SPECIFIC TO TRANSTHYRETIN CARDIAC AMYLOID (2010) (0)
Sensitive MRI markers for systemic amyloidosis : amide proton transfer and equilibrium contrast (2010) (0)
Methods Patient Identification in the General Heart Failure (2016) (0)
Serum Amyloid P Component Scintigraphy in Alzheimer's Disease (1996) (0)
3 year follow-up results on a treatment for amyloid A (AA) amyloidosis (2006) (0)
LIVER TRANSPLANTATION FOR END STAGE HEPATIC AMYLOIDOSIS.: Abstract# 105 (2000) (0)
257 Carpal Tunnel Biopsy as a Diagnostic Tool to Identify Early Cases of Cardiac Amyloidosis: Results of a Pilot Study (2016) (0)
Cardiac Resynchronization Therapyfor End-Stage Hypertrophic Cardiomyopathy (2018) (0)
ARFs get the BioID treatment: what have we been missing? (2022) (0)
AB0901 TWO TYPES OF SYSTEMIC AMYLOIDOSIS IN A SINGLE PATIENT (2019) (0)
18 Quantitative CMR myocardial perfusion mapping to assess hyperaemic response to adenosine stress: a new reference standard? (2019) (0)
A profile of 44 long term survivors (> 10yrs) with AL amyloidosis (2007) (0)
A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis (2014) (0)
The Authors Reply. (2020) (0)
006 Role of T1 mapping as a complementary tool to T2* for non-invasive cardiac iron overload assessment (2017) (0)
CARDIAC UPTAKE IN AL AMYLOIDOSIS OF 99MTC-DPD AS A NOVEL MARKER OF POOR PROGNOSIS IN SYSTEMIC AL AMYLOIDOSIS (2016) (0)
Amyloidosis and Primary Biliary Cirrhosis, Rodriguez-Luna Et Al. (2006) (0)
How a Drug is Assessed Once It ’ s in Clinical Trials : A Perspective from a Clinical Pharmacology Reviewer (2018) (0)
We look forward to clarification from The International Myeloma Working Group on this matter. (2005) (0)
Atrial strain in cardiacATTR amyloidosis from pathophysiology to prognosis: is it time to rethink our approach to disease? (2020) (0)
Automated Pixel-Wise Quantitative Myocardial Perfusion Mapping by Cardiovascular Magnetic Resonance to Detect Obstructive Coronary Artery Disease and Coronary Microvascular Dysfunction: Validation Against Invasive Coronary Physiology (2019) (0)
An evaluation of current treatment options for immunoglobulin light-chain amyloidosis (2014) (0)
PI3Ks in inflammation (2009) (0)
024 Spectrum and significance of CMR findings in cardiac transthyretin amyloidosis (2017) (0)
Michael Wakelam (15 July 1955–31 March 2020) (2020) (0)
17 Fat water imaging for sub-epicardial gadolinium: enhancing the diagnosis of myocarditis (2019) (0)
Structural and Functional Studies of Serum Amyloid P Component (1991) (0)
P2-307: CPHPC depletes serum amyloid P component from the cerebrospinal fluid in Alzheimer's disease (2008) (0)
Comparison of 99mTc-DPD Scintigraphy, CMR Imaging, and Echocardiography in Patients With V30M-Associated Hereditary Transthyretin Amyloidosis. (2022) (0)
Reply (2018) (0)
Adaptations of Receptor-Dependent Phosphatidylinositol 4,5-Bisphosphate Breakdown (1987) (0)
Cardiac Followed by Autologous Stem Cell Transplantation for Systemic AL Amyloidosis. (2005) (0)
Systemic Diseases (2010) (0)
A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis (2019) (0)
Linking changes in quality of life to haematologic response and survival in systemic immunoglobulin light‐chain amyloidosis (2023) (0)
Signalling via PI3Ks (2000) (0)
Chapter 14 AMicro-SPECT / CTSystemfor ImagingofAA-Amyloidosis in Mice (2006) (0)
Remarkable Efficacy of IL 1 Receptor Antagonist In Schnitzler's Syndrome a Series of 6 Cases (2010) (0)
Long‐term outcomes in light chain deposition disease‐analysis of a UK cohort (2022) (0)
lymphoma . AL kappa amyloid in a solitary extradural (0)
EQUILIBRIUM CONTRAST MRI: MEASURING TISSUE INTERSTITIAL VOLUME IN HEALTH AND AMYLOIDOSIS (2019) (0)
Hyphae Aspergillus fumigatus Response to Regulate Neutrophil Oxidase Activation in d and b Class IA Phosphoinositide 3-Kinase (2011) (0)
Prospective screening of Afro-Caribbean heart failure patients to determine the prevalence of cardiac transthyretin (ATTR) amyloidosis (2013) (0)
Cardiac transthyretin (ATTR) amyloidosis - clinical and echocardiographic findings from the largest single cohort worldwide (2013) (0)
Cytokines and Inflammatory Mediators [30–39] 30. The LPS Stimulated Production of Interleukin-10 is not Associated with -819C/T and -592C/A Promoter Polymorphisms in Healthy Indian Subjects (2010) (0)
Late onset of the cryopyrin-associated periodic syndrome (CAPS) associated with low level of somatic mosaicism in six patients (2015) (0)
Search for a genetic susceptibility factor ( s ) in Schnitzler ’ s syndrome (2017) (0)
Title Structure , Folding Dynamics , and Amyloidogenesis of D 76 N β 2-Microglobulin : ROLES OF SHEAR FLOW , HYDROPHOBIC SURFACES (0)
PB2127 BORTEZOMIB-HIGH DOSE METHYLPREDNISOLONE OFFERS IMPROVED HAEMATOLOGICAL RESPONSES AND OVERALL SURVIVAL COMPARED TO BORTEZOMIB-DEXAMETHASONE IN SYSTEMIC LIGHT CHAIN AMYLOIDOSIS (2019) (0)
Vilasack Thammavongsa Promote Immune Cell Death Degrades Neutrophil Extracellular Traps to Staphylococcus aureus (2013) (0)
Myocardial fibrosis quantification by cardiac CT predicts outcome in severe aortic stenosis (2021) (0)
The National Amyloidosis Centre, Royal Free Hospital and UCL, London (2019) (0)
Clinical features and management of amyloidosis (2003) (0)
189 PREVALENCE, DISEASE CHARACTERISTICS AND OUTCOMES OF HEREDITARY TRANSTHYRETIN AMYLOID CARDIOMYOPATHY AMONG ELDERLY INDIVIDUALS (2022) (0)
Native T 1 and ECV in ATTR amyloidosis (2018) (0)
Age-related decline in the resistance of mice to bacterial infection and in LPS/TLR4 pathway-dependent neutrophil responses (2022) (0)
Autologous stem cell transplantation versus bortezomib for the first line treatment of systemic light chain amyloidosis in the UK (2021) (0)
AB0071 SERUM S100A8/A9 (CALPROTECTIN) IN FAMILIAL MEDITERRANEAN FEVER DOES NOT CORRELATE WITH DISEASE ACTIVITY (2019) (0)
S148 Regulation of neutrophil apoptosis by phosphoinositide 3-kinases (2010) (0)
Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel (2017) (0)
High prevalence of sleep disordered breathing (SDB) in patients with systemic AL amyloidosis (2014) (0)
Advances in Non-Invasive Imaging of Aa Amyloid in Mice (2007) (0)
Abstract 16829: Myocardial Extracellular Volume Fraction and Survival in Systemic AL Amyloidosis (2013) (0)
319Myocardial perfusion mapping in cardiac amyloidosis: transformation from a disease of solely infiltration to myocardial ischaemia (2019) (0)
Imaging cardiac ATTR amyloid (2015) (0)
TRPML1: A novel therapeutic target to remediate endolysosomal pathology in Alzheimer’s disease (2020) (0)
Heavy/light chain immunoparesis identifies systemic AL amyloidosis patients with poor survival outcomes (2015) (0)
Abstract 14709: Dual Pathology of Severe Aortic Stenosis and Cardiac Amyloidosis: Multi-center Study of Prevalence and Outcome (2020) (0)
A simple assay method fordetermination ofthespecific radioactivity ofthe y-phosphate group of32P-labelled ATP (1983) (0)
Signalling via PI3-kinases (2001) (0)
RapidAutomatedEnzymeImmunoassay of SerumAmyloidA (1994) (0)
The UK Experience of Renal Transplantation in AL Amyloidosis (2019) (0)
Cardiac Magnetic Resonance derived Extracellular Volume Mapping for the quantification of hepatic and splenic amyloid Short title: Quantifying extra-cardiac amyloid with ECV mapping (2021) (0)
Monitoring amyloid deposition and therapeutic clearance using equilibrium contrast MRI (2011) (0)
054 Adult Periodic Fevers, Apthous Ulceration, Pharyngitis and Adenitis: A Single-Centre Experience (2016) (0)
Ras G12V - PI 3-kinase gamma complex (2001) (0)
Orthotopic liver transplantation for patients with familial amyloid polyneuropathy: a national centre experience (2016) (0)
Abstract 14123: Assessment of Treatment Response in Cardiac AL Amyloidosis Using CMR Mapping - Results at 3 Months, 6 Months and 1 Year Post-Chemotherapy (2018) (0)
Amyloidosis: Immunopathogenesis and diagnosis (2012) (0)
FRI0537 LONG-TERM OUTCOMES AND TREATMENT EFFICACY IN PATIENTS WITH TNF RECEPTOR-ASSOCIATED AUTOINFLAMMATORY SYNDROME (TRAPS): A SERIES OF 290 CASES FROM THE EUROFEVER/EUROTRAPS INTERNATIONAL REGISTRY (2019) (0)
CLINICAL AND BIOCHEMICAL OUTCOME OF HEPATORENAL TRANSPLANTATION FOR HEREDITARY SYSTEMIC AMYLOIDOSIS ASSOCIATED WITH APOLIPOPROTEIN AI Gly26Arg1 (2001) (0)
Phosphatidylinositol-3-phosphate and inositol phosphates in mitogenesis. (1990) (0)
Hereditary periodic fever syndromes (2010) (0)
Familial amyloid polyneuropathy: the importance of cardiac involvement (2015) (0)
Validation ofnovel analytical techniques byusing 32P-labelied lipids fromerythrocytes (1984) (0)
FRI0599 AA AMYLOIDOSIS IN RECIPIENTS OF CADAVERIC DERIVED PITUITARY GROWTH HORMONE – POTENTIAL EFFECT OF AN AMYLOID ENHANCING FACTOR? (2019) (0)
Reductions in extracellular volume by magnetic resonance indicate ATTR cardiac amyloid regression with patisiran (2021) (0)
Transthyretin-related Familial Amyloid Polyneuropathy (TTR-FAP) caused by a very rare, de novo mutation in a Polish patient. (2015) (0)
Identification of phosphoinositide-binding proteins by using phosphoinositide-coupled affinity matrices (2001) (0)
The inositol-3-phosphate synthase biosynthetic enzyme has distinct catalytic and 1 metabolic roles 2 3 4 (2016) (0)
Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience (2022) (0)
Searching for novel targets of PtdIns(3,4,5)P3 and PtdIns(3,4)P2 (1999) (0)
REGRESSION OF AMYLOIDOSIS DEMONSTRATED BY SAP SCINTIGRAPHY (1993) (0)
Contents Vol. 94, 2003 (2003) (0)
Pathogenetic mechanisms of AA amyloidosis Short title : Pathogenesis of AA amyloidosis (2013) (0)
AMYLOIDOSIS IN CAPTIVE EUROPEAN EASTERN BONGO (TRAGELAPHUS EURYCERUS ISAACI): PREVALENCE, PREDICTIVE FACTORS, ORGAN PREDILECTION, AND SERUM AMYLOID A CONCENTRATIONS (2023) (0)
Synthesis of Dipalmitoyl Phosphatidylinositol 3,4‐Bis(phosphate) and 3,4,5‐Tris(phosphate) and Their Enantiomers. (1998) (0)
Images in cardiovascular medicine. Intermittent loss of second heart sound. (2006) (0)
Mechano-enzymatic cleavage and TTR amyloidogenesis (2017) (0)
Signalling from cell surface receptors: molecular mechanisms and physiological significance of the phosphoinositide 3-kinase signalling system (2009) (0)

This paper list is powered by the following services:

Other Resources About Phillip Thomas Hawkins

en.wikipedia.org

What Schools Are Affiliated With Phillip Thomas Hawkins?

Phillip Thomas Hawkins is affiliated with the following schools:

Phillip Thomas Hawkins's Academic­Influence.com Rankings

Phillip Thomas Hawkins's Degrees

Why Is Phillip Thomas Hawkins Influential?

Phillip Thomas Hawkins's Published Works

Published Works

Other Resources About Phillip Thomas Hawkins

What Schools Are Affiliated With Phillip Thomas Hawkins?

Phillip Thomas Hawkins's AcademicInfluence.com Rankings